IDEAYA Biosciences (IDYA) Liabilities and Shareholders Equity (2018 - 2026)

IDEAYA Biosciences has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $1.0 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.0 billion, down 6.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 billion (down 1.63% YoY), and the FY2025 annual result was $1.1 billion, down 1.31% from the prior year.
• Liabilities and Shareholders Equity came in at $1.0 billion for Q1 2026 at IDEAYA Biosciences, down from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2024 to a low of $338.0 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $961.5 million (2024), against an average of $784.5 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 163.62% in 2024 and decreased 6.39% in 2026, its largest moves.
• IDEAYA Biosciences' Liabilities and Shareholders Equity stood at $388.0 million in 2022, then surged by 67.36% to $649.3 million in 2023, then soared by 73.12% to $1.1 billion in 2024, then retreated by 1.31% to $1.1 billion in 2025, then declined by 7.12% to $1.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.